Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (571-580 of 869) with videos related to

Pageof 87
Sort By:
Blood|January 14, 2017
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaTeru Hideshima, Francesca Cottini, Yoshihisa Nozawa, et al.
Nature Medicine|February 15, 2024
Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityDouglas W McMillin, Jake Delmore, Ellen Weisberg, et al.
Cancer Cell|March 31, 2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaAnil Aktas Samur, Jill Corre, Srikanth Talluri, et al.
British Journal of Haematology|June 6, 2003
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myelomaBritta Maecker, Karen S Anderson, Michael S von Bergwelt-Baildon, et al.
Nature Communications|February 9, 2021
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myelomaMehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, et al.
British Journal of Haematology|June 29, 2006
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cellsPaola Neri, Hiroshi Yasui, Teru Hideshima, et al.
Nature Medicine|March 16, 2010
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityDouglas W McMillin, Jake Delmore, Ellen Weisberg, et al.
British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
Pageof 87

Showing results (571-580 of 869) with videos related to

Sort By:
Pageof 87
Blood|January 14, 2017
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myelomaTeru Hideshima, Francesca Cottini, Yoshihisa Nozawa, et al.
Nature Medicine|February 15, 2024
Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityDouglas W McMillin, Jake Delmore, Ellen Weisberg, et al.
Cancer Cell|March 31, 2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaAnil Aktas Samur, Jill Corre, Srikanth Talluri, et al.
British Journal of Haematology|June 6, 2003
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myelomaBritta Maecker, Karen S Anderson, Michael S von Bergwelt-Baildon, et al.
Nature Communications|February 9, 2021
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myelomaMehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, et al.
British Journal of Haematology|June 29, 2006
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cellsPaola Neri, Hiroshi Yasui, Teru Hideshima, et al.
Nature Medicine|March 16, 2010
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activityDouglas W McMillin, Jake Delmore, Ellen Weisberg, et al.
British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
Pageof 87